Comparing Lyell Immunopharma (NASDAQ:LYEL) and Celularity (NASDAQ:CELU)

Lyell Immunopharma (NASDAQ:LYELGet Rating) and Celularity (NASDAQ:CELUGet Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Lyell Immunopharma and Celularity’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lyell Immunopharma N/A N/A N/A
Celularity N/A 71.61% 6.07%

Earnings & Valuation

This table compares Lyell Immunopharma and Celularity’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lyell Immunopharma $10.65 million 105.80 -$250.22 million N/A N/A
Celularity $21.33 million 43.00 -$100.12 million N/A N/A

Celularity has higher revenue and earnings than Lyell Immunopharma.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Lyell Immunopharma and Celularity, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lyell Immunopharma 0 0 4 0 3.00
Celularity 0 2 1 0 2.33

Lyell Immunopharma currently has a consensus target price of $22.00, indicating a potential upside of 382.46%. Celularity has a consensus target price of $9.67, indicating a potential upside of 45.15%. Given Lyell Immunopharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Lyell Immunopharma is more favorable than Celularity.

Institutional and Insider Ownership

44.8% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 12.1% of Celularity shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lyell Immunopharma beats Celularity on 5 of the 9 factors compared between the two stocks.

About Lyell Immunopharma (Get Rating)

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Celularity (Get Rating)

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase 1 clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase 1 clinical trial to treat acute myeloid leukemia, as well as in Phase 1/2a clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase 1 clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.